IQVIA Holdings Inc. (NYSE:IQV) Holdings Cut by USS Investment Management Ltd

USS Investment Management Ltd lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,771 shares of the medical research company's stock after selling 3,783 shares during the period. USS Investment Management Ltd's holdings in IQVIA were worth $5,460,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of IQV. Voloridge Investment Management LLC raised its holdings in shares of IQVIA by 325.7% during the fourth quarter. Voloridge Investment Management LLC now owns 194,103 shares of the medical research company's stock valued at $38,143,000 after buying an additional 148,512 shares during the last quarter. Waverly Advisors LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $626,000. Worldquant Millennium Advisors LLC raised its holdings in shares of IQVIA by 1,537.3% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 235,444 shares of the medical research company's stock valued at $46,267,000 after buying an additional 221,064 shares during the last quarter. Sone Capital Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $6,595,000. Finally, Wexford Capital LP raised its holdings in shares of IQVIA by 64.8% during the fourth quarter. Wexford Capital LP now owns 1,569 shares of the medical research company's stock valued at $308,000 after buying an additional 617 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 0.4%

IQVIA stock opened at $137.90 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $23.86 billion, a price-to-earnings ratio of 18.39, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1 year low of $135.39 and a 1 year high of $252.88. The firm's 50 day moving average price is $156.36 and its two-hundred day moving average price is $184.15.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.54 earnings per share. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday. Truist Financial cut their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Robert W. Baird lowered their price objective on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $228.14.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.